1. Home
  2. ELF vs TGTX Comparison

ELF vs TGTX Comparison

Compare ELF & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo e.l.f. Beauty Inc.

ELF

e.l.f. Beauty Inc.

HOLD

Current Price

$80.44

Market Cap

4.8B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.81

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELF
TGTX
Founded
2004
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
5.5B
IPO Year
2016
1995

Fundamental Metrics

Financial Performance
Metric
ELF
TGTX
Price
$80.44
$30.81
Analyst Decision
Buy
Strong Buy
Analyst Count
16
4
Target Price
$127.00
$54.75
AVG Volume (30 Days)
1.8M
1.4M
Earning Date
02-05-2026
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.40
2.78
Revenue
$1,385,640,000.00
$531,898,000.00
Revenue This Year
$20.59
$87.88
Revenue Next Year
$16.79
$48.75
P/E Ratio
$57.51
$11.08
Revenue Growth
13.80
100.88
52 Week Low
$49.40
$25.28
52 Week High
$150.99
$46.48

Technical Indicators

Market Signals
Indicator
ELF
TGTX
Relative Strength Index (RSI) 47.66 46.32
Support Level $76.51 $29.79
Resistance Level $82.19 $31.37
Average True Range (ATR) 3.10 1.00
MACD 1.44 0.04
Stochastic Oscillator 71.68 47.47

Price Performance

Historical Comparison
ELF
TGTX

About ELF e.l.f. Beauty Inc.

e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: